Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11.

Katsumi T, Guicciardi ME, Azad A, Bronk SF, Krishnan A, Gores GJ.

Am J Physiol Cell Physiol. 2019 Oct 1;317(4):C788-C799. doi: 10.1152/ajpcell.00250.2019. Epub 2019 Jul 31.

PMID:
31365294
2.

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.

Guicciardi ME, Trussoni CE, Krishnan A, Bronk SF, Lorenzo Pisarello MJ, O'Hara SP, Splinter PL, Gao Y, Vig P, Revzin A, LaRusso NF, Gores GJ.

J Hepatol. 2018 Sep;69(3):676-686. doi: 10.1016/j.jhep.2018.05.018. Epub 2018 May 24.

3.

YAP-associated chromosomal instability and cholangiocarcinoma in mice.

Rizvi S, Fischbach SR, Bronk SF, Hirsova P, Krishnan A, Dhanasekaran R, Smadbeck JB, Smoot RL, Vasmatzis G, Gores GJ.

Oncotarget. 2017 Dec 22;9(5):5892-5905. doi: 10.18632/oncotarget.23638. eCollection 2018 Jan 19.

4.

Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.

Kabashima A, Hirsova P, Bronk SF, Hernandez MC, Truty MJ, Rizvi S, Kaufmann SH, Gores GJ.

J Hepatol. 2018 Jun;68(6):1228-1238. doi: 10.1016/j.jhep.2018.01.026. Epub 2018 Mar 9.

5.

TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity.

Hirsova P, Weng P, Salim W, Bronk SF, Griffith TS, Ibrahim SH, Gores GJ.

Hepatol Commun. 2017 Sep;1(7):648-662. doi: 10.1002/hep4.1069. Epub 2017 Jul 20.

6.

Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.

Smoot RL, Werneburg NW, Sugihara T, Hernandez MC, Yang L, Mehner C, Graham RP, Bronk SF, Truty MJ, Gores GJ.

J Cell Biochem. 2018 Jan;119(1):824-836. doi: 10.1002/jcb.26246. Epub 2017 Aug 3.

7.

Mixed Lineage Kinase 3 Mediates the Induction of CXCL10 by a STAT1-Dependent Mechanism During Hepatocyte Lipotoxicity.

Tomita K, Kabashima A, Freeman BL, Bronk SF, Hirsova P, Ibrahim SH.

J Cell Biochem. 2017 Oct;118(10):3249-3259. doi: 10.1002/jcb.25973. Epub 2017 May 15.

8.

Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice.

Guicciardi ME, Krishnan A, Bronk SF, Hirsova P, Griffith TS, Gores GJ.

Cell Death Dis. 2017 Jan 5;8(1):e2535. doi: 10.1038/cddis.2016.459.

9.

CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis.

Tomita K, Freeman BL, Bronk SF, LeBrasseur NK, White TA, Hirsova P, Ibrahim SH.

Sci Rep. 2016 Jun 28;6:28786. doi: 10.1038/srep28786.

10.

A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.

Rizvi S, Yamada D, Hirsova P, Bronk SF, Werneburg NW, Krishnan A, Salim W, Zhang L, Trushina E, Truty MJ, Gores GJ.

J Biol Chem. 2016 Apr 8;291(15):8031-47. doi: 10.1074/jbc.M115.698472. Epub 2016 Jan 29.

11.

Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.

Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Werneburg NW, Charlton MR, Shah VH, Malhi H, Gores GJ.

Gastroenterology. 2016 Apr;150(4):956-67. doi: 10.1053/j.gastro.2015.12.037. Epub 2016 Jan 5.

12.

Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes.

Ibrahim SH, Hirsova P, Tomita K, Bronk SF, Werneburg NW, Harrison SA, Goodfellow VS, Malhi H, Gores GJ.

Hepatology. 2016 Mar;63(3):731-44. doi: 10.1002/hep.28252. Epub 2015 Dec 11. Erratum in: Hepatology. 2016 Aug;64(2):702.

13.

Lipoapoptosis induced by saturated free fatty acids stimulates monocyte migration: a novel role for Pannexin1 in liver cells.

Xiao F, Waldrop SL, Bronk SF, Gores GJ, Davis LS, Kilic G.

Purinergic Signal. 2015 Sep;11(3):347-59. doi: 10.1007/s11302-015-9456-5. Epub 2015 Jun 9.

14.

IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism.

Yamada D, Rizvi S, Razumilava N, Bronk SF, Davila JI, Champion MD, Borad MJ, Bezerra JA, Chen X, Gores GJ.

Hepatology. 2015 May;61(5):1627-42. doi: 10.1002/hep.27687. Epub 2015 Mar 20.

15.

TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess.

Idrissova L, Malhi H, Werneburg NW, LeBrasseur NK, Bronk SF, Fingas C, Tchkonia T, Pirtskhalava T, White TA, Stout MB, Hirsova P, Krishnan A, Liedtke C, Trautwein C, Finnberg N, El-Deiry WS, Kirkland JL, Gores GJ.

J Hepatol. 2015 May;62(5):1156-63. doi: 10.1016/j.jhep.2014.11.033. Epub 2014 Nov 28.

16.

Decreasing mitochondrial fission prevents cholestatic liver injury.

Yu T, Wang L, Lee H, O'Brien DK, Bronk SF, Gores GJ, Yoon Y.

J Biol Chem. 2014 Dec 5;289(49):34074-88. doi: 10.1074/jbc.M114.588616. Epub 2014 Oct 23.

17.

Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis.

Rizvi S, Mertens JC, Bronk SF, Hirsova P, Dai H, Roberts LR, Kaufmann SH, Gores GJ.

J Biol Chem. 2014 Aug 15;289(33):22835-49. doi: 10.1074/jbc.M114.563064. Epub 2014 Jun 27.

18.

Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity.

Guicciardi ME, Werneburg NW, Bronk SF, Franke A, Yagita H, Thomas G, Gores GJ.

PLoS One. 2014 Mar 14;9(3):e92124. doi: 10.1371/journal.pone.0092124. eCollection 2014.

19.

Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma.

Razumilava N, Gradilone SA, Smoot RL, Mertens JC, Bronk SF, Sirica AE, Gores GJ.

J Hepatol. 2014 Mar;60(3):599-605. doi: 10.1016/j.jhep.2013.11.005. Epub 2013 Nov 14. Erratum in: J Hepatol. 2014 Jul;61(1):185.

20.

Degradation of cIAPs contributes to hepatocyte lipoapoptosis.

Akazawa Y, Guicciardi ME, Cazanave SC, Bronk SF, Werneburg NW, Kakisaka K, Nakao K, Gores GJ.

Am J Physiol Gastrointest Liver Physiol. 2013 Nov;305(9):G611-9. doi: 10.1152/ajpgi.00111.2013. Epub 2013 Sep 5.

21.

Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis.

Hirsova P, Ibrahim SH, Bronk SF, Yagita H, Gores GJ.

PLoS One. 2013 Jul 22;8(7):e70599. doi: 10.1371/journal.pone.0070599. Print 2013.

22.

Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.

Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, Rizvi SH, Canbay A, Treckmann JW, Paul A, Sirica AE, Gores GJ.

Hepatology. 2013 Oct;58(4):1362-74. doi: 10.1002/hep.26484. Epub 2013 Aug 6.

23.

Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.

Mertens JC, Fingas CD, Christensen JD, Smoot RL, Bronk SF, Werneburg NW, Gustafson MP, Dietz AB, Roberts LR, Sirica AE, Gores GJ.

Cancer Res. 2013 Jan 15;73(2):897-907. doi: 10.1158/0008-5472.CAN-12-2130. Epub 2012 Dec 5.

24.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2).

Werneburg NW, Bronk SF, Guicciardi ME, Thomas L, Dikeakos JD, Thomas G, Gores GJ.

J Biol Chem. 2012 Jul 13;287(29):24427-37. doi: 10.1074/jbc.M112.342238. Epub 2012 May 29.

25.

A hedgehog survival pathway in 'undead' lipotoxic hepatocytes.

Kakisaka K, Cazanave SC, Werneburg NW, Razumilava N, Mertens JC, Bronk SF, Gores GJ.

J Hepatol. 2012 Oct;57(4):844-51. doi: 10.1016/j.jhep.2012.05.011. Epub 2012 May 26.

26.

Targeting PDGFR-β in Cholangiocarcinoma.

Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ.

Liver Int. 2012 Mar;32(3):400-9. doi: 10.1111/j.1478-3231.2011.02687.x. Epub 2011 Dec 2.

27.

Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells.

Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, Mertens JC, Sirica AE, Gores GJ.

Hepatology. 2011 Dec;54(6):2076-88. doi: 10.1002/hep.24588.

28.

Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis.

Kakisaka K, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Werneburg NW, Mott JL, Gores GJ.

Am J Physiol Gastrointest Liver Physiol. 2012 Jan 1;302(1):G77-84. doi: 10.1152/ajpgi.00301.2011. Epub 2011 Oct 13.

29.

miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma.

Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg NW, Roberts LR, Mott JL.

Hepatology. 2012 Feb;55(2):465-75. doi: 10.1002/hep.24698. Epub 2011 Dec 19.

30.

Death receptor 5 signaling promotes hepatocyte lipoapoptosis.

Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ.

J Biol Chem. 2011 Nov 11;286(45):39336-48. doi: 10.1074/jbc.M111.280420. Epub 2011 Sep 22.

31.

A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA.

Cazanave SC, Mott JL, Elmi NA, Bronk SF, Masuoka HC, Charlton MR, Gores GJ.

J Lipid Res. 2011 Aug;52(8):1517-25. doi: 10.1194/jlr.M014654. Epub 2011 Jun 1.

32.

Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cells.

Kurita S, Mott JL, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Roberts LR, Fernandez-Zapico ME, Gores GJ.

PLoS One. 2011 Mar 31;6(3):e18330. doi: 10.1371/journal.pone.0018330.

33.

Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis.

Ibrahim SH, Akazawa Y, Cazanave SC, Bronk SF, Elmi NA, Werneburg NW, Billadeau DD, Gores GJ.

J Hepatol. 2011 Apr;54(4):765-72. doi: 10.1016/j.jhep.2010.09.039. Epub 2010 Nov 23.

34.

Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.

Guicciardi ME, Mott JL, Bronk SF, Kurita S, Fingas CD, Gores GJ.

Exp Cell Res. 2011 Jan 1;317(1):107-16. doi: 10.1016/j.yexcr.2010.10.005. Epub 2010 Oct 14.

35.

A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells.

Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, Werneburg NW, Sirica AE, Gores GJ.

Hepatology. 2010 Aug;52(2):550-61. doi: 10.1002/hep.23729.

36.

Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB.

Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME.

J Cell Biochem. 2010 Aug 1;110(5):1155-64. doi: 10.1002/jcb.22630.

37.

GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis.

Kurita S, Mott JL, Almada LL, Bronk SF, Werneburg NW, Sun SY, Roberts LR, Fernandez-Zapico ME, Gores GJ.

Oncogene. 2010 Aug 26;29(34):4848-58. doi: 10.1038/onc.2010.235. Epub 2010 Jun 21.

38.

Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition.

Sosa Seda IM, Mott JL, Akazawa Y, Barreyro FJ, Bronk SF, Kaufmann SH, Gores GJ.

Hepatol Res. 2010 Jul 1;40(7):701-10. doi: 10.1111/j.1872-034X.2010.00668.x. Epub 2010 Jun 14.

39.

CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis.

Cazanave SC, Elmi NA, Akazawa Y, Bronk SF, Mott JL, Gores GJ.

Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G236-43. doi: 10.1152/ajpgi.00091.2010. Epub 2010 Apr 29.

40.

Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis.

Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, Charlton MR, Gores GJ.

J Hepatol. 2010 Apr;52(4):586-93. doi: 10.1016/j.jhep.2010.01.003. Epub 2010 Feb 13.

41.

A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells.

Smoot RL, Blechacz BR, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, Gores GJ.

Cancer Res. 2010 Mar 1;70(5):1960-9. doi: 10.1158/0008-5472.CAN-09-3535. Epub 2010 Feb 16.

42.

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.

Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ.

Hepatology. 2009 Dec;50(6):1861-70. doi: 10.1002/hep.23214.

43.

Mcl-1 degradation during hepatocyte lipoapoptosis.

Masuoka HC, Mott J, Bronk SF, Werneburg NW, Akazawa Y, Kaufmann SH, Gores GJ.

J Biol Chem. 2009 Oct 30;284(44):30039-48. doi: 10.1074/jbc.M109.039545. Epub 2009 Sep 5.

44.

JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis.

Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ.

J Biol Chem. 2009 Sep 25;284(39):26591-602. doi: 10.1074/jbc.M109.022491. Epub 2009 Jul 28.

45.

Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Kahraman A, Bronk SF, Cazanave S, Werneburg NW, Mott JL, Contreras PC, Gores GJ.

Hepatol Res. 2009 Aug;39(8):805-13. doi: 10.1111/j.1872-034X.2009.00541.x. Epub 2009 Jul 13.

46.

Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines.

Akazawa Y, Mott JL, Bronk SF, Werneburg NW, Kahraman A, Guicciardi ME, Meng XW, Kohno S, Shah VH, Kaufmann SH, McNiven MA, Gores GJ.

Gastroenterology. 2009 Jun;136(7):2365-2376.e1-7. doi: 10.1053/j.gastro.2009.02.071. Epub 2009 Mar 9.

47.

Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Kahraman A, Mott JL, Bronk SF, Werneburg NW, Barreyro FJ, Guicciardi ME, Akazawa Y, Braley K, Craig RW, Gores GJ.

Dig Dis Sci. 2009 Sep;54(9):1908-17. doi: 10.1007/s10620-008-0583-5. Epub 2008 Dec 3.

48.

BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis.

Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ.

Mol Cancer Ther. 2008 Aug;7(8):2339-47. doi: 10.1158/1535-7163.MCT-08-0285.

49.

Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species.

Langer DA, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk SF, Katusic ZS, Gores GJ, Shah VH.

Hepatology. 2008 Jun;47(6):1983-93. doi: 10.1002/hep.22285.

50.

TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse.

Kahraman A, Barreyro FJ, Bronk SF, Werneburg NW, Mott JL, Akazawa Y, Masuoka HC, Howe CL, Gores GJ.

Hepatology. 2008 Apr;47(4):1317-30. doi: 10.1002/hep.22136.

Supplemental Content

Loading ...
Support Center